Vaccine against SARS-CoV-2 based on non-infectious replicons

Study on the development of a prototype vaccine against SARS-CoV-2 that can be administered intranasally in a single dose


Interview with Sonia Zúñiga, virologist and researcher at Centro Nacional de Biotecnología del Centro Superior de Investigaciones Científicas (CSIC) about this study. Source: ConSalud.es

Description of the Study:

  • Title: Desarrollo de una vacuna contra el SARS-CoV-2 basada en replicones no infectivos.
  • Principal Investigators: Luis Enjuanes, Isabel Sola y Sonia Zuñiga.
  • Centers of Implementation: Consejo Superior de Investigaciones Científicas (CSIC). 
  • Study Population: Trials with mice and hamsters are forthcoming.
  • Study type: Study based on laboratory research. Clinical trial coming soon.
  • Design: Defined RNA replicon, which multiplies the gene dose that triggers protection but complementary technologies are needed for vaccine delivery.

Objectives of the Study:

Principal Objective: To generate SARS-CoV-2 virus in the laboratory by assembling synthetic DNA fragments and to eliminate from its genome the genes responsible for virulence using reverse genetics techniques to introduce attenuating mutations and obtain non-infectious and highly immunogenic derivatives as vaccine candidates against SARS-CoV-2.

Secondary objective: Development of animal models (transgenic mice) for the validation of vaccines and other therapeutic agents against COVID-19.

More about this Study:

It is an original vaccine based on the genetic manipulation of SARS-CoV-2 itself, from which we have derived an RNA replicon that multiplies the gene dose that triggers protection. This vaccine includes mutations of the UK, South African and Brazilian viruses, and probably also of a US variant that has appeared in California and New York.

It is also self-amplifying, which means that the dose of RNA injected can multiply 5,000 times inside the body. It also generates a sterilizing immunity, i.e. vaccinated people not only do not get sick, but also do not become infected and do not transmit the virus.

On the other hand, administration could be intranasal. The mucous membranes (nasal, ocular, respiratory, etc.) are spaces open to the exterior and immunity in these areas is best induced locally, presenting the antigen there. This virus enters our body primarily through the respiratory tract.

Unnamed 3

Other Studies:

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

Uogup

An antiviral mouthwash and COVID-19

Using a mouthwash containing β-cyclodextrin and citrox (bioflavonoids) (CDCM), available in pharmacies, helps reduce the SARS-CoV-2 viral load in saliva.

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age.

LacCOVID Study

The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.